Jason P Haack, MD | |
191 Overthrust Rd, Evanston, WY 82930-9261 | |
(307) 789-8721 | |
(307) 789-8664 |
Full Name | Jason P Haack |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 22 Years |
Location | 191 Overthrust Rd, Evanston, Wyoming |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1407832728 | NPI | - | NPPES |
06329001 | Other | WY | BCBS WY |
1407832728 | Medicaid | WY | |
433920700 | Medicaid | MN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207YX0905X | Otolaryngology - Otolaryngology/facial Plastic Surgery | 7953A (Wyoming) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Evanston Regional Hospital | Evanston, WY | Hospital |
Memorial Hospital Sweetwater County | Rock springs, WY | Hospital |
Cheyenne Regional Medical Center | Cheyenne, WY | Hospital |
Entity Name | Southwest Wyoming Ent Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1730335423 PECOS PAC ID: 0244306678 Enrollment ID: O20080908000493 |
News Archive
American Medical Alert Corp. a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter ended March 31, 2011, the
Mr. Ryan's Path To Prosperity blueprint includes more than $700 billion in Medicare cuts over the next decade. Medicare would no longer function as an insurance program that directly pays medical bills for seniors. Instead, seniors would receive a fixed subsidy. The value of that subsidy almost certainly wouldn't keep up with health care costs, meaning seniors would pay more out of pocket. That might not play well in Boca Raton. Of course, Mr. Ryan's just the prospective V.P. What does the top of the ticket think?
Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition.
Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.
New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Jason P Haack, MD 191 Overthrust Rd, Evanston, WY 82930-9261 Ph: (307) 789-8721 | Jason P Haack, MD 191 Overthrust Rd, Evanston, WY 82930-9261 Ph: (307) 789-8721 |
News Archive
American Medical Alert Corp. a provider of healthcare communication services and advanced telehealth monitoring technologies, today announced operating results for the quarter ended March 31, 2011, the
Mr. Ryan's Path To Prosperity blueprint includes more than $700 billion in Medicare cuts over the next decade. Medicare would no longer function as an insurance program that directly pays medical bills for seniors. Instead, seniors would receive a fixed subsidy. The value of that subsidy almost certainly wouldn't keep up with health care costs, meaning seniors would pay more out of pocket. That might not play well in Boca Raton. Of course, Mr. Ryan's just the prospective V.P. What does the top of the ticket think?
Researchers at University College London say they have gleaned a key insight into the molecular beginnings of age-related macular degeneration, the No. 1 cause of vision loss in the elderly, by determining how two key proteins interact to naturally prevent the onset of the condition.
Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.
New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.
› Verified 1 days ago